木防己汤加减联合丹红注射液治疗慢性肺源性心脏病急性发作期疗效探讨

目的:探讨木防己汤加减联合丹红注射液治疗慢性肺源性心脏病急性发作期临床效果。方法:研究对象选取海口市中医医院近年来收治慢性肺源性心脏病急性发作期饮郁化热证患者130例,采用随机数字表法分为对照组和观察组,每组各65例;两组患者均给予西医常规对症支持治疗;其中对照组患者采用丹红注射液治疗,观察组患者则在对照组基础上加用木防己汤加减辅助治疗;比较两组患者临床疗效、治疗前后中医证候积分、心功能分级、肺功能指标、血气分析指标及血液流变学指标水平等。结果:观察组患者临床疗效显著优于对照组,差异有统计学意义(P0.05);观察组患者治疗后中医证候积分显著优于对照组、治疗前,差异有统计学意义(P0.05);观察组患者治疗后心功能分级、肺功能指标、血气分析指标及血液流变学指标水平均显著优于对照组、治疗前,差异有统计学意义(P0.05)。结论:木防己汤加减联合丹红注射液治疗慢性肺源性心脏病急性发作期可有效缓解临床症状体征,改善心肺功能,并有助于降低血液黏稠度。

Clinical Effects of Mufangji Tang Combined with Danhong Injection in Treatment of Chronic Pulmonary Heart Disease at Acute Exacerbation Stage

Objective: To investigate the clinical effects of Mufangji Tang combined with Danhong injection in the treatment of chronic pulmonary heart disease at acute exacerbation stage. Method: The 130 patients with chronic pulmonary heart disease at acute exacerbation stage in recent years in our hospital were chosen and randomly divided into control group (65 patients) with Danhong injection and observation group (65 patients) with Mufangji Tang on the basis of conventional western medicine treatment. The clinical efficacy, traditional Chinese medicine(TCM) syndrome scores, cardiac function grading, levels of pulmonary function, blood gas analysis and blood rheology indexes before and after treatment of both groups were compared. Result: The clinical efficacy of observation group was significantly better than that of control group, with statistically significant difference (P<0.05). The TCM syndrome scores after treatment in observation group were significantly better than those of control group and those before treatment, with statistically significant difference (P<0.05). The cardiac function grading, levels of pulmonary function, blood gas analysis and blood rheology indexes after treatment in observation group were significantly better than those in control group and those before treatmentwith statistically significant difference (P<0.05). Conclusion: Mufangji Tang combined with Danhong injection in the treatment of chronic pulmonary heart disease at acute exacerbation stage can efficiently relieve clinical symptoms and signs, improve heart and lung functions and help to reduce the degree of blood viscosity.